


User interface images for each study-related educational decision support feature.

The screenshot shows a 'WizOrder PopUp' window for a female patient. At the top, it displays 'female, MR#' and 'weight= kgs, CrCl=7ml/min'. The interface is divided into several colored sections:

- Cultures (Red):** A table with columns for Culture date, Pathogen, Source, and Remarks. The entry shows 'Mar 31 05:14 MODERATE GROWTH STAPHYLOCOCCUS COAGULASE POS. PERITONEAL FLUID'.
- Current ABx (Blue):** Lists 'CEFAZOLIN INJ: ANCEF (cefazolin inj: ancef 250 mg peridial prn »Apr 2 16:57...)' and 'GENTAMICIN INJ: GARAMYCIN (gentamicin inj: garamycin 8 mg peridial prn »Apr 2 17:44...)'.
- Suggested ABx (Green):** Features a prominent red warning: 'WARNING: This is an experimental system. It has not been fully validated yet.' Below this is a table with columns for Cost/day, Antibiotics, and Remarks. It shows '\$2' for cost, 'vancomycin IV 130mg q12' for the antibiotic, and 'RECOMMENDED TREATMENT. Need to adjust subsequent doses of vancomycin for renal function..' for the remark. An 'order' button is present next to the antibiotic name.
- Actions (Yellow):** A row of buttons: 'current regimen is appropriate', 'no suggestion is appropriate', 'defer choice to next session', and 'view more details'.

ABA, Antibiotic Advisor, triggered from positive blood cultures. Provided antibiotics recommendations based on organism-specific and institutional drug sensitivity patterns.



MSH, triggered from an active diagnosis order. Performed a real-time keyword search in the online interface to the PubMed database.

Chemistry and Stability

Chemistry

Amiodarone hydrochloride is an iodinated benzofuran-derivative antiarrhythmic agent.(1-6,13,25) The drug differs structurally and pharmacologically from other currently available antiarrhythmic agents.(1-6,13,25)

Amiodarone hydrochloride occurs as a white to cream-colored, crystalline powder(1,355) and has solubilities of approximately 0.72 mg/mL in water and 12.8 mg/mL in alcohol at 25DGC.(241) The drug is highly lipophilic.(1,241) Amiodarone hydrochloride contains 37.3% iodine; each 200-mg tablet of the drug or each mL of the commercially available injection contains approximately 75 or 18.7 mg of iodine, respectively.(1,2,13) Amiodarone has a pKa of approximately 6.6.(2,241,283)

Stability

Amiodarone hydrochloride tablets should be protected from light(1,242) and stored in tight containers(1,283) at room temperature (about 25DGC).(1) Commercially available amiodarone tablets have an expiration date of 3 years following the date of manufacture.(283)

Commercially available amiodarone hydrochloride injection should be stored at room temperature (i.e., 15-25DGC) and protected from light and excessive heat.(355) Ampuls containing the injection should be stored in the carton to protect the solution from light until used.(355) Diluted solutions of amiodarone hydrochloride injection do not need to be protected from light during administration.(355)

Although amiodarone hydrochloride adsorbs to polyvinyl chloride (PVC) tubing, the parenteral drug doses and administration schedule studied in clinical trials were designed to take this fact into account.(355) Therefore, the manufacturer recommends using PVC tubing and closely following the suggested infusion regimen when administering amiodarone hydrochloride by IV infusion.(355)

Following dilution of amiodarone hydrochloride injection to a concentration of 1-6 mg/mL in 5% dextrose in a PVC container, there is physical compatibility, with a loss of less than 10% of drug at 2 hours.(355) Following dilution of amiodarone hydrochloride injection to a concentration of 1-6 mg/mL in 5% dextrose in a glass or polyolefin container, there is physical compatibility, with no loss of drug at 24 hours.(355) Therefore, the manufacturer states that

WRX, triggered from new medication orders. Displayed drug monographs from the American Hospital Formulary Service (AHFS) Drug Information reference database.

1998 Mosby's GenRx
The Complete Reference for Generic and Brand Drugs

History: Amiodarone Hydrochloride

Browse by:
Enter the first few letters
then click:

- Keyword
- Drug Name
- FDA Drug Class
- Indications
- Drug Master Plus
- Interactions
- USP Off-Label Uses
- Suppliers
- Full Word Search

Contents:
[top](#)
[Interacts With](#)
[Prescribing Info:](#)

[ORAL Doseform](#)
[Description](#)
[Clinical Pharmacology](#)
[Indications and Usage](#)
[Contraindications](#)
[Warnings](#)
[Precautions](#)
[Drug Interactions](#)
[Adverse Reactions](#)

Amiodarone Hydrochloride (000212)

Categories: [Arrhythmia, ventricular](#); [Fibrillation, ventricular](#); [Tachycardia, ventricular](#); [Pregnancy Category D](#); [FDA Approved 1985 Dec](#); [Orphan Drugs](#)

Vol. I Off-Label Uses: Arrhythmias, supraventricular (prophylaxis); Arrhythmias, supraventricular (treatment)

FDA Drug Class: Antianginals; Antiarrhythmics

Brand Names: Aldarin, Aldarone, Amidodacore, Amiorit, Amiodarona, Amiorone, Ancaron, Angoron, Aratac, Atlansil, Braxan, Cardarone, Cardiorona, Corbionax, Cordarex, Cordaron, **Cordarone**, Cordarone I.V., Cordarone X, Coronova, Kendaron, Myodura, Procor, Rythmarone, Sedacoron, Tachydaron, Tlaryt, Trangorex
(Foreign brand names outside U.S. in italics)

Cost of Therapy: \$1,339.98 (Arrhythmia; Tablet; 200 mg; 2/day; 365 days)

ORAL Doseform

Description:

Cordarone is a member of a new class of antiarrhythmic drugs with predominantly Class III (Vaughan Williams' classification) effects.

[Add to My List](#)

USP DI,

MSB, triggered from new medication orders. Displayed drug monographs from Mosby's GenRx® drug information reference.

The screenshot displays a clinical decision support interface. On the left side, there are two sections: 'FINDINGS' and 'DISEASES'. Under 'FINDINGS', there are radio buttons for 'present', 'ignore', 'absent', and 'drop', with 'present' selected. Below this, there are two findings listed: 'cough (2)' and 'cough chronic productive hx (2)'. Under 'DISEASES', there are radio buttons for 'present', 'ignore', 'absent', and 'drop', with 'present' selected. Below this, there are two diseases listed: 'pneumococcal pneumonia'. There are also buttons for 'Generate hypotheses/scenarios', 'Add finding/disease', 'Rule-in disease(s)', and 'Rule-out disease(s)'. On the right side, there is a section titled 'RESULTS (hypotheses, scenarios)'. It contains a 'Considering:' section with a long list of diseases and their associated counts. Below this, there is a section titled 'A single disease explains all manifestations' with a list of diseases and their counts.

FINDINGS

present ignore absent drop

cough (2)

cough chronic productive hx (2)

DISEASES

present ignore absent drop

pneumococcal pneumonia

Generate hypotheses/scenarios

explain findings

explain findings and diseases

Add finding/disease

Rule-in disease(s)

Rule-out disease(s)

RESULTS (hypotheses, scenarios)

Considering: bronchitis chronic (simple) 13/13; bronchiectasis 5/5; cystic fibrosis (adult form) 5/5; tuberculosis chronic pulmonary 5/5; bronchial asthma 4/4; pulmonary emphysema 4/4; coccidioidomycosis chronic pulmonary 2/2; histoplasmosis chronic pulmonary 2/2; lymphomatoid granulomatosis 2/2; pulmonary abscess 2/2; pulmonary alveolar proteinosis 2/2; pulmonary anthracosis 2/2; pulmonary asbestosis 2/2; pulmonary atypical mycobacterial infection 2/2; pulmonary malignant neoplasm secondary (lymphogenous type) 2/2; pulmonary nocardiosis 2/2; pulmonary silicosis chronic 2/2; sporotrichosis systemic 2/2; amebic liver abscess 1/1; angioimmunoblastic lymphadenopathy 1/1; aortic dissection 1/1; aspergillosis disseminated 1/1; aspiration pneumonia 1/1; atelectasis 1/1; atypical mycobacterial infection disseminated 1/1; blastomycosis chronic pulmonary 1/1; blastomycosis disseminated 1/1; bronchiolar-alveolar cell carcinoma 1/1; bronchogenic carcinoma squamous cell type 1/1; brucellosis 1/1; bronchial carcinoid neoplasm 1/1; carcinoid syndrome 1/1; carcinoma of esophagus 1/1; cat scratch disease 1/1; ceramide trihexoside lipoidosis (Fabry's disease) 1/1; cervicofacial actinomycosis 1/1; coccidioidomycosis disseminated 1/1; coccidioidomycosis primary pulmonary 1/1; cryoglobulinemic syndrome 1/1; cytomegalovirus pneumonia 1/1; disseminated intravascular coagulation 1/1; echinococcal cyst (s) of liver 1/1; endocarditis infective right heart 1/1; eosinophilic pneumonia acute (Loeffler) 1/1; eosinophilic pneumonia chronic 1/1; erythroleukemia 1/1; Goodpasture syndrome (pulmonary component) 1/1; Gram negative pneumonia (non klebsiella) 1/1; Henoch Schonlein syndrome 1/1; histoplasmosis disseminated 1/1; histoplasmosis primary pulmonary 1/1; infectious mononucleosis 1/1; influenza 1/1; influenza pneumonia 1/1; klebsiella pneumonia 1/1; pulmonary legionellosis 1/1; leptospirosis systemic 1/1; leukemia acute lymphoblastic 1/1; leukemia acute monocytic or myelomonocytic 1/1; leukemia acute myeloblastic 1/1; leukemia chronic myelocytic in myeloblastic crisis 1/1; lupus erythematosus systemic 1/1; Lyme disease 1/1; malaria 1/1; Mallory Weiss syndrome 1/1; meningococcal meningitis 1/1; meningococcemia acute 1/1; mycoplasma pneumonia 1/1; pericardial effusion without tamponade 1/1; plague pneumonia 1/1; pleural malignant mesothelioma 1/1; pneumococcal meningitis 1/1; pneumococcal pneumonia 1/1/1; pneumocystis pneumonia 1/1; progressive systemic sclerosis 1/1; psittacosis 1/1; pulmonary aspergillosis invasive type 1/1; pulmonary aspergillosis mycetoma type 1/1; pulmonary candidiasis 1/1; pulmonary congestion acute cardiogenic 1/1; pulmonary congestion chronic cardiogenic 1/1; pulmonary cryptococcosis 1/1; pulmonary histiocytosis 1/1; pulmonary hypertension primary 1/1; pulmonary infarction 1/1; pulmonary interstitial fibrosis idiopathic 1/1; pulmonary interstitial fibrosis secondary diffuse 1/1; pulmonary lymphoma 1/1; pulmonary malignant neoplasm secondary (hematogenous type) 1/1; pulmonary veno-occlusive disease 1/1; reflux esophagitis 1/1; relapsing polychondritis 1/1; rhinocerebral mucormycosis (phycomycosis) 1/1; rocky mountain spotted fever 1/1; sarcoidosis chronic pulmonary 1/1; sarcoidosis chronic systemic 1/1; sarcoidosis primary transient 1/1; schistosomiasis systemic 1/1; Sjogren's syndrome 1/1; sphingomyelin lipoidosis (adult form) 1/1;

A single disease explains all manifestations

13 bronchitis chronic (simple)

5 bronchiectasis

5 cystic fibrosis (adult form)

5 tuberculosis chronic pulmonary


2 coccidioidomycosis chronic pulmonary

2 histoplasmosis chronic pulmonary


2 lymphomatoid granulomatosis

QMR, triggered from active diagnosis and medication orders. Provided access to an internal medicine diagnostic knowledge base and diagnostic expert system listing the findings that have been reported to occur in 600 diseases in Internal Medicine, and the differential diagnosis of over 4,500 individual clinical findings



Alarming Values/Trends



Watch These Borderline Values/Trends



Normal Values/Trends



TRD, triggered off of the results of 21 individual laboratory tests for those that were “clinically abnormal” or those having a trend suggesting that an abnormal value would occur within the next 72 hours. Provided access to graphical display of pertinent laboratory trends.

dep.	order	instances	cost per instance	cost
LAB	CBC / PLT CT	1	63.00	63.00
PHM	AMIODARONE: CORDARONE	10	11.28	112.80
Total for new lab tests, medications, radiology exams:				\$175.80

LMR, triggered off of orders for laboratory tests, medications and radiology procedures. Provided access to a display that gave a detailed tally of “estimated expenditures” from during the current order entry session.